13F Holdings
中文EN

TLSA Tiziana Life Sciences Ltd IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1723069 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY32.9%
TTM EPS YoY35.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-250.5%
ROA-101.1%
ROIC (approx.)-546.6%
Asset turnover—

Leverage & solvency

Liabilities / assets65.1%
Debt / equity0.00x
Current ratio1.02x
Interest coverage-8.94x

Cash quality & payout

Operating cash flow / net income0.13x
Accruals ratio-88.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31FY2020*2020-12-31
Income statement
Revenue—————
R&D expense$5.23M$8.11M$12.96M$13.21M$5.99M
Operating income-$15.79M-$17.98M-$14.59M-$27.37M-$28.03M
Interest expense$1.77M$412,000$876,000——
Pretax income-$16.75M-$17.24M-$15.40M-$26.66M-$28.34M
Income tax-$4.88M$449,000—-$3.24M-$2.21M
Net income-$11.86M-$17.69M-$15.40M-$23.42M-$26.13M
EPS (basic)-0.11-0.17-0.15-0.24-0.16
EPS (diluted)-0.11-0.17-0.15-0.24-0.16
Balance sheet
Cash & equivalents$3.72M$1.18M$18.12M$42.19M$65.82M
Current assets$7.51M$7.34M$24.28M$48.68M$70.18M
PP&E, netmay include right-of-use assets (IFRS)$16,000$10,000$17,000$17,000$3,000
Intangibles———$130,000$120,000
Total assets$11.28M$12.18M$26.48M$48.83M$70.66M
Current liabilities$7.35M$6.54M$6.66M$7.55M$7.98M
Total liabilities$7.35M$6.65M$6.91M$7.55M$8.27M
Shareholders' equity$3.94M$5.54M$19.57M$41.28M$62.39M
Cash flow statement
Operating cash flow-$1.53M-$15.70M-$19.61M-$21.76M-$11.34M
Capital expenditure$19,000——$22,000$3,000
Free cash flow-$1.54M——-$21.78M-$11.34M
Investing cash flow-$71,000-$1.25M-$4.00M$130,000-$123,000
Financing cash flow$4.50M$40,000-$55,000-$23,000$75.35M
Stock-based compensation$910,000$1.73M-$1.41M$5.17M$26,000

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.